Literature DB >> 12655530

Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs.

Joshua E Muscat1, Shu-Quan Chen, John P Richie, Nasser K Altorki, Marc Citron, Sara Olson, Alfred I Neugut, Steven D Stellman.   

Abstract

BACKGROUND: Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the development of lung tumors in experimental animals. To the authors' knowledge there are little data regarding whether regular use of NSAIDs reduces the risk of developing lung carcinoma in humans.
METHODS: The association between lung carcinoma risk and regular use of NSAIDs, including aspirin, was evaluated in a hospital-based case-control study of 1038 patients and 1002 controls.
RESULTS: The relative risk estimate of lung carcinoma associated with using NSAIDs 3 times a week or more for 1 or more years demonstrated an odds ratio (OR) of 0.68 (95% confidence interval [95% CI], 0.53-0.89). Results were similar when separated by lung histologic type. The association varied by smoking status. The OR was 1.28 (95% CI, 0.73-2.25) in never-smokers and 0.60 (95% CI 0.45-0.80) in ever-smokers. The smoking-specific risk estimates for aspirin were similar to those for all NSAIDs.
CONCLUSIONS: The results of the current study suggest a possible chemoprotective benefit with the use of NSAIDs among individuals who are former or current smokers. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11242

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655530     DOI: 10.1002/cncr.11242

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO).

Authors:  Valerie A McCormack; Rayjean J Hung; Darren R Brenner; Heike Bickeböller; Albert Rosenberger; Joshua E Muscat; Philip Lazarus; Anne Tjønneland; Søren Friis; David C Christiani; Eun-Mi Chun; Loic Le Marchand; Gad Rennert; Hedy S Rennert; Angeline S Andrew; Irene Orlow; Bernard Park; Paolo Boffetta; Eric J Duell
Journal:  Cancer Causes Control       Date:  2011-10-11       Impact factor: 2.506

2.  Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.

Authors:  Michele L Coté; Mei Liu; Stefano Bonassi; Monica Neri; Ann G Schwartz; David C Christiani; Margaret R Spitz; Joshua E Muscat; Gad Rennert; Katja K Aben; Angeline S Andrew; Vladimir Bencko; Heike Bickeböller; Paolo Boffetta; Paul Brennan; Hermann Brenner; Eric J Duell; Eleonora Fabianova; John K Field; Lenka Foretova; Søren Friis; Curtis C Harris; Ivana Holcatova; Yun-Chul Hong; Dolores Isla; Vladimir Janout; Lambertus A Kiemeney; Chikako Kiyohara; Qing Lan; Philip Lazarus; Jolanta Lissowska; Loic Le Marchand; Dana Mates; Keitaro Matsuo; Jose I Mayordomo; John R McLaughlin; Hal Morgenstern; Heiko Müeller; Irene Orlow; Bernard J Park; Mila Pinchev; Olaide Y Raji; Hedy S Rennert; Peter Rudnai; Adeline Seow; Isabelle Stucker; Neonila Szeszenia-Dabrowska; M Dawn Teare; Anne Tjønnelan; Donatella Ugolini; Henricus F M van der Heijden; Erich Wichmann; John K Wiencke; Penella J Woll; Ping Yang; David Zaridze; Zuo-Feng Zhang; Carol J Etzel; Rayjean J Hung
Journal:  Eur J Cancer       Date:  2012-03-19       Impact factor: 9.162

3.  Elevated plasma 8-iso-prostaglandin F levels in human smokers originate primarily from enzymatic instead of non-enzymatic lipid peroxidation.

Authors:  Thomas J van 't Erve; Fred B Lih; Maria B Kadiiska; Leesa J Deterding; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2017-11-21       Impact factor: 7.376

4.  Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.

Authors:  Pamela L Rice; Bradley S Barrett; Jason M Fritz; Mary C Srebernak; Lori R Kisley; Alvin M Malkinson; Lori D Dwyer-Nield
Journal:  Exp Lung Res       Date:  2010-11       Impact factor: 2.459

5.  Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in the VITAL study.

Authors:  Theodore M Brasky; Christina S Baik; Christopher G Slatore; John D Potter; Emily White
Journal:  Lung Cancer       Date:  2012-05-17       Impact factor: 5.705

6.  Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.

Authors:  Laura P Stabile; Mariya Farooqui; Beatriz Kanterewicz; Shira Abberbock; Brenda F Kurland; Brenda Diergaarde; Jill M Siegfried
Journal:  J Thorac Oncol       Date:  2017-12-09       Impact factor: 15.609

7.  The use of Cox-2 and PPARγ signaling in anti-cancer therapies.

Authors:  Lucia Knopfová; Jan Smarda
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

Review 8.  NSAIDs inhibit tumorigenesis, but how?

Authors:  Evrim Gurpinar; William E Grizzle; Gary A Piazza
Journal:  Clin Cancer Res       Date:  2013-12-05       Impact factor: 12.531

9.  Racial and Ethnic Differences in the Relationship between Aspirin Use and Non-Small Cell Lung Cancer Risk and Survival.

Authors:  Patricia Erickson; Lisa D Gardner; Christopher A Loffredo; Diane Marie St George; Elise D Bowman; Janaki Deepak; Khadijah Mitchell; Claire L Meaney; Patricia Langenberg; Debra H Bernat; Sania Amr; Bríd M Ryan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-31       Impact factor: 4.254

10.  Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.

Authors:  Yu Jiang; Zixuan Su; Caichen Li; Jianxing He; Wenhua Liang; Runchen Wang; Yaokai Wen; Hengrui Liang
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-23       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.